Cellective BioTherapy
Innovative therapies harnessing B cell-based solutions for cancer, autoimmune diseases, and immunodeficiency.
Innovative therapies harnessing B cell-based solutions for cancer, autoimmune diseases, and immunodeficiency.
Cellective BioTherapy is a biotechnology company that focuses on developing innovative therapies utilizing B cell-based solutions for cancer, autoimmune diseases, and immunodeficiency. Since its establishment in 2015, the company has been dedicated to creating cellular and monoclonal antibody-based platforms to address a range of health challenges. Their R&D efforts are centered on B cell-based cellular therapies intended for immunomodulation, immunodeficiency, and autoimmune conditions.
This forward-thinking startup's research extends to various medical areas, including cancer, diabetes, asthma, congenital and acquired immunodeficiency, and vaccine development. In June 2015, Cellective BioTherapy secured a significant $2.50M Angel Round investment from Eshelman Ventures, demonstrating strong investor confidence in the company's potential for medical innovation and impact.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Angel Round | $2.50M | 1 |
|
12 Jun 2015 |
| Venture Round | Unknown | 1 |
|
01 Jan 2004 |
No recent news or press coverage available for Cellective BioTherapy.
We care about your data, and we'd love to use cookies make your experience better.
